| Chemotherapy |
Chemotherapy continues to
be a viable treatment option in the advanced/metastatic
breast cancer
setting for ER-negative cancers or ER-positive
breast cancers no longer responsive to hormonal
therapy. Numerous options exist in terms of single-agent
or combination regimens, and the optimal regimen
for each patient will largely depend
upon the response of the tumor to the treatment
and the side effects of the chemotherapy. Improved
mechanisms of delivering cytotoxic drugs that
allow better tolerability and dosing efficacy
are currently under evaluation. |
| |
Interactive Case Study
|
 |
December 2007
1 AMA PRA Category
1 Credit™
Expiration date: December 28, 2008
- Treatment Options for a Patient With Metastatic Breast Cancer Who Cannot Receive a Conventional Taxane
|
|
 |
December 2007
1 AMA PRA Category
1 Credit™
Expiration date: December 22, 2008
- Treatment Options for Patients With Metastatic Breast Cancer in the First-line Setting
|
|
 |
December 2007
1 AMA PRA Category
1 Credit™
Expiration date: December 18, 2008
- Treatment Options for Therapy of Metastatic Breast Cancer Pretreated With Anthracyclines and Taxanes
|
|
 |
December 2007
1 AMA PRA Category
1 Credit™
Expiration date: December 19, 2008
- Treatment Options for Metastatic Breast Cancer Previously Treated With Anthracyclines, Taxanes, and Capecitabine
|
|
 |
June 2007
1 AMA PRA Category
1 Credit™
Expiration date: June 30, 2008
- Treatment Options for HER2-Negative Metastatic Breast Cancer
|
|
| |
LECTURES
|
Rapid Reviews in Oncology: Emerging Options in the Treatment of Breast Cancer
1.5 AMA PRA Category
1 Credits™
Expiration date: July 2, 2009 |
Sixth International Symposium on Supportive Care in Oncology: Cancer Management in the Era of Targeted Agents
February 22-23, 2008
New York, NY |
|
Breast Cancer Highlights: Updates from the 2007 San Antonio Breast Cancer Symposium
January 31, 2008
Kansas City, MO |
|
Breast Cancer Highlights: Updates from the 2007 San Antonio Breast Cancer Symposium
January 24, 2008
Atlanta, GA |
|
Contemporary Trends in Chemotherapy for Advanced/Metastatic Breast Cancer
December 14, 2007
San Antonio, TX
|
|
New Strategies for Targeting Microtubules in Breast Cancer
October 12, 2007
New York, NY
Presentations From a Satellite Symposium Held in Conjunction With the Controversies in Breast Cancer Adjuvant and Neoadjuvant Therapy 2007 Congress |
|
| Translating the Complexities of Cancer Development Into Novel Therapeutics
|
|
Controversies in Biologic Therapy of Breast Cancer
September 7, 2007
San Francisco, CA |
|
2 AMA PRA Category
1 Credits™
Expiration date: September 24, 2008 |
Beyond Taxanes: New Chemotherapeutic Options for Patients With Refractory Metastatic Breast Cancer
September 7, 2007
San Francisco, CA |
|
2 AMA PRA Category
1 Credits™
Expiration date: September 24, 2008 |
Advances in Microtubule-Targeting Strategies In Breast Cancer
July 27, 2007
Kohala Coast, HI |
|
1 AMA PRA Category
1 Credit™
Expiration date: August 31, 2008 |
Emerging Strategies in Breast Cancer: Targeting Tomorrow’s Therapies Today
May 12, 2007
Boston, MA
- Using Genomic Tools in Patient Selection for Adjuvant Chemotherapy
- Proteomics, Kinomics, and Other Predictive Tools
- Next-Generation Adjuvant Chemotherapies: Integrating Antimetabolites and Biologics
- Epothilones
- Novel Vinca Alkaloids and Other Mictrotubule-Targeting Agents
- Targeting HER2 in Early Breast Cancer: Optimizing Therapy
- Dual ErbB1/ErbB2 Kinase Inhibitors
Targeting the VEGF/VEGFR Pathway: Antibodies, Small-Molecule TKIs, Decoy Receptors, and Other Novel Approaches
- Mechanisms of Endocrine Resistance and New Targets for Clinical Research
- Nausea and Vomiting - Emerging Agents and New Formulations
- Targeting RANK/RANKL, Cathepsin K, TGF-Beta and Other New Signaling Pathways
- Novel Agents for the Treatment or Prevention of Hematopoietic Adverse Events (Neutropenia, Thrombocytopenia, and Anemia)
|
| |
Current Trends in Breast Cancer
January 13, 20-February 3, 24, 2007
2007 Series
- New Developments in Adjuvant Chemotherapy
- Controversies in Adjuvant Hormonal Therapy
- Adjuvant HER2-Directed Therapy: Candidates and Practical Management
- Novel Preoperative Therapy Strategies
- Treatment Insights Based on Molecular Subtypes and Novel Diagnostics
- New Insights Into Optimizing Local Control
- Evolving Chemotherapies and Hormonal Therapies for Metastatic Breast Cancer
- Novel Biologic Agents With Clinical Promise
- Management of Therapy-Related Toxicities
- Focus on the Host: Evolving Concepts
|
|
|
Controversies in Breast Cancer Adjuvant and Neoadjuvant Therapy 2006
September 8-10, 2006 |
- Key Diagnostic Assessments in Breast Cancer
- Evolving Local Control Issues in Breast Cancer
- Treatment of Hormone Receptor–Positive Breast Cancer
- Adjuvant Treatment of HER2-Driven Breast Cancer
- Treating ER, PR, HER2-Negative Breast Cancer
- Lifestyle, Genetics, and Breast Cancer Outcome
|
|
5th Annual International Congress on the Future of Breast Cancer
August 3-6, 2006
- Best of Breast Cancer Research
- Optimizing Endocrine Therapy
- Molecular Mechanisms of Endocrine Resistance
- Supportive Care Breakfast Symposium
- Predictive and Prognostic Factors for Adjuvant Therapy
- Emerging Chemotherapy Strategies
- Targeting the HER Axis in Breast Cancer
- Targeting Angiogenesis in Breast Cancer
- New Agents Breakfast Symposium
- Impact of Local Control on Overall Outcomes
- Maintaining Bone Health
- Optimizing Chemotherapy
- Practical Issues in Breast Cancer Treatment
- Breast Cancer Genetics and Biology
|
|
|
|
|
| |
| PUBLICATIONS |
 |
Vol. 3, No. 1
1 AMA
PRA Category 1 Credit™
Expiration date: June 6, 2009
-
Management of Platinum-Resistant Ovarian Cancer
|
|
 |
May 2008
1 AMA
PRA Category 1 Credit™
Expiration date: June 6, 2009
-
Management of Platinum-Resistant Ovarian Cancer
|
|
 |
April 2008
1 AMA
PRA Category 1 Credit™
Expiration date: June 4, 2009
- Targeting Growth Factor Receptors: Current Impact and Future Potential
- Therapeutic Applications of Angiogenesis-Based Therapies
|
|
 |
Vol. 5, No. 2
1 AMA
PRA Category 1 Credit™
Expiration date: May 6, 2009
- Lapatinib/Capecitabine for ErbB2-Positive Advanced Breast Cancer
- Cardiac Safety of Doxorubicin/Cyclophosphamide Followed by Paclitaxel ± Trastuzumab
- Phase II Study of Predictive Biomarker Profiles With Lapatinib in IBC
- Trastuzumab/Tanespimycin in Trastuzumab-Refractory ErbB2-Positive Breast Cancer
|
|
 |
February
2008
1 AMA
PRA Category 1 Credits™
Expiration date: March 10, 2009
- Single vs. Combination Therapy: Which Agents and What Clinical Situation?
- Chemotherapy and Biologically Targeted Agents: Synergy and Side-Effect Profile
- LABC as aModel for the Study and Optimization of Chemotherapeutic Regimens
- Protein and Genetic Markers in Deciding Optimal Chemotherapy
|
|
 |
Vol. 8, Suppl. 1
1.5 AMA
PRA Category 1 Credit™
Expiration date: March 3, 2009
- Advances in Chemotherapy and Supportive Therapy for Breast Cancer
|
|
 |
Vol. 4, No. 12
1 AMA
PRA Category 1 Credit™
Expiration date: March 3, 2009
- Treatment of HER2-Positive/Hormone Receptor–Positive Metastatic Breast Cancer With Endocrine Therapy Plus HER2-Targeted Therapy
|
|
 |
Vol. 5, No. 10
1 AMA PRA
Category 1 Credit™
Expiration date: December 26, 2008
- Treatment of a Patient With Relapsed ErbB2-Positive Metastatic Breast Cancer With Lapatinib
|
|
 |
December 2007
1 AMA PRA
Category 1 Credit™
Expiration date: December 22, 2008
- Who Needs Adjuvant HER2-Targeted
Therapy?
- Novel Therapies for HER2-Positive Breast
Cancer
- Confusion on the HER2 Front: Not All
Decisions
Are Black and White
- Inhibiting the Tumor Microenvironment
- Targeting Oncogene Addiction in Breast
Cancer:
Key Pathways and Novel Targets
|
|
 |
Vol. 8, No. 4
1 AMA PRA
Category 1 Credit™
Expiration date: December 14, 2008
- Rationale and Clinical Data for Combined Inhibition of HER2 and Vascular Endothelial Growth Factor Receptor Pathways in Breast Cancer
- Genomic Rearrangements in Breast
Cancer: Clinical Implications
- Putative Breast Cancer Stem Cells as Therapeutic Targets
|
|
 |
December 2007
1 AMA PRA
Category 1 Credit™
Expiration date: December 14, 2008
- Controversies in Adjuvant Therapy: Treatment Options for Patients With Node-Negative, HER2-Positive, Early-Stage Breast Cancer
- Controversies in Metastatic Breast Cancer: Treatment Options for HER2-Positive Disease
- Controversies in Metastatic Breast Cancer: Treatment Options for HER2-Negative Disease
|
|
 |
November 2007
1 AMA PRA
Category 1 Credit™
Expiration date: November 20, 2008
- History of Microtubule-Targeted Agents in Breast Cancer as a Model for Drug Development
- Novel Microtubule-Targeting Agents in Clinical Development in Breast Cancer
|
|
 |
November 2007
1 AMA
PRA Category 1 Credit™
Expiration date: November 20, 2007
- Targeting Signaling Pathways to Inhibit Cancer Growth
- Targeting the MAP/MEK and PI3K/Akt Pathways
- Novel Small-Molecular Inhibitors Targeting VEGFR in Breast Cancer
- Vaccines in Lung Cancer
- Novel Immunologic Targets in Metastatic Melanoma
- Combining Targeted Agents to Improve Therapeutic Efficacy
|
|
 |
November 2007
1 AMA PRA
Category 1 Credit™
Expiration date: November 20, 2008
- Optimizing Adjuvant Therapy With HER2-Targeted MoAbs
- Clinical Utility and Future Prospects of Small-Molecule HER TKIs
- Breast Cancer Resistant to HER2-Targeted Therapies
- Clinical Utility and the Future of Angiogenesis Inhibitor Therapy
- Emerging Applications of IGF-1R–Targeted Therapy
|
|
 |
November 2007
1 AMA PRA
Category 1 Credit™
Expiration date: November 20, 2008
- HER2-Targeted Therapy in Early-Stage Breast Cancer
- Emerging Targeting Agents in HER2+ Breast Cancer
- Angiogenesis Inhibition in Advanced Breast Cancer
- Multiplying the Benefits: Novel Combinations of Targeted Agents
- c-Myc Amplification and Other Genetic Alterations in HER2+ Breast Cancer
|
|
 |
Vol. 5, No. 8
1 AMA PRA
Category 1 Credit™
Expiration date: November 20, 2008
- Paclitaxel Formulations in MBC
|
|
 |
November 2007
1 AMA
PRA Category 1 Credit™
Expiration date: November 20, 2008
- Combining VEGF and EGFR Inhibition in NSCLC
- Second-Generation Inhibitors of the VEGFR Tyrosine Kinase
- Small-Molecule TKIs in the Treatment of Advanced Thyroid Cancer
- Harnessing SPARC Protein for Uptake of Chemotherapy in Tumors
- Current Data on Raf/MEK Inhibitors in Melanoma and Other Cancers
- Understanding the Kinome and Its Role in Cancer Pathogenesis
|
|
 |
Vol. 7, Suppl. 1
1.5 AMA
PRA Category 1 Credit™
Expiration date: October 31, 2008
- Evolving Strategies in the Maintenance of Bone Health in Breast Cancer
|
|
 |
August
2007
1 AMA
PRA Category 1 Credit™
Expiration date: August 31, 2008
- Increasing the Therapeutic Index of Traditional Chemotherapeutics
- Role of the Tumor Stroma in Breast Cancer and Treatment
- Immune-Mediated Antitumor Effects With Antibody Therapy
|
|
 |
August
2007
1 AMA
PRA Category 1 Credit™
Expiration date: August 31, 2008
- Novel Microtubule-Targeting
Agents in MBC
- Epothilones and Other Novel
Microtubule-Targeting Agents
in MBC
|
|
 |
May
2007
1.75 AMA PRA
Category 1 Credits™
Expiration date: May 31, 2008
- SPARC in Tumorigenesis
- Novel Taxane Formulations in Breast
Cancer
- Aromatase Inhibitor Treatment Options
in Hormone Receptor–Positive
Early-Stage Breast Cancer
|
|
 |
April
2007, Vol. 5, No. 8
1 AMA PRA
Category 1 Credit™
Expiration date: April 30, 2008
- Albumin-Bound Paclitaxel/Bevacizumab
in MBC
|
|
 |
January 2007, Vol. 5, No.2
1 AMA
PRA Category 1 Credit™
Expiration date: January 31, 2008
- Albumin-Bound Paclitaxel for Metastatic Breast Cancer
|
|
| |
|
